CRSP - CRISPR Therapeutics AG
| Previous Close | 48.86 |
| Open | 48.24 |
| Bid | 45.50 x 1000 |
| Ask | 47.80 x 1300 |
| Day's Range | 46.13 - 49.38 |
| 52 Week Range | 22.22 - 59.00 |
| Volume | 373,533 |
| Avg. Volume | 568,923 |
| Market Cap | 2.549B |
| Beta (3Y Monthly) | 3.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.92 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 62.35 |
- Zacks
Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
- Motley Fool
Vertex Has "Significant Financial Firepower"
A dominant cystic fibrosis franchise drives cash flow.
- Zacks
Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View
Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.
- American City Business Journals
Legal fight over Broad Institute's patent for CRISPR gene editing flares up again
The legal battle over a method of altering a person’s genes that’s worth billions of dollars escalated this week, with the University of California alleging that the Cambridge-based Broad Institute withheld information in an attempt to deceive U.S. patent officials.
- Motley Fool
Is Intellia Therapeutics a Buy?
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
- GlobeNewswire
CRISPR Therapeutics to Present at Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., July 31, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
- Zacks
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -24.69% and -97.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
-Provides update in ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Enrolling in Phase 1/2 clinical trial of CTX110™, targeting.
- Zacks
Axovant (AXGT) to Post Q1 Earnings: What's in the Cards?
On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.
- Zacks
Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.
- Motley Fool
Where Will CRISPR Therapeutics Be in 5 Years?
Investors have high hopes for the $2.7 billion gene editing pioneer, yet there are reasons for both optimism and pessimism.
- Benzinga
Jim Cramer Gives His Opinion On eBay, Pfizer And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said eBay Inc (NASDAQ: EBAY ) is going much higher. He explained that it's splitting up and bringing out value. Cloudera Inc (NYSE: CLDR ) missed ...
- Motley Fool
Is Vertex Pharmaceuticals a Buy?
This company is making drug development look much easier than it really is.
- Motley Fool
CRISPR Could Change Medicine, But Not in the Way Wall Street Expects
The gene-editing approach might prove more useful outside the clinic.
- Motley Fool
2 Supercharged Growth Stocks I'd Buy Right Now
CRISPR Therapeutics and Curaleaf Holdings could have a lot more room to run.
- Zacks
Can We Find The Right Stock Using Our Newly Found Insight?
Can We Find The Right Stock Using Our Newly Found Insight?
- Zacks
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
- Zacks
Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.
- Motley Fool
Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
- GlobeNewswire
CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes
ZUG, Switzerland and CAMBRIDGE, Mass., July 01, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
- Motley Fool
3 Growth Stocks to Buy and Hold for the Next 50 Years
This alcohol maker, drug company, and utility should generate steady growth for their investors in the decades ahead.
- Insider Monkey
Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ?
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
- Simply Wall St.
What Kind Of Shareholders Own CRISPR Therapeutics AG (NASDAQ:CRSP)?
The big shareholder groups in CRISPR Therapeutics AG (NASDAQ:CRSP) have power over the company. Generally speaking, as...
- Simply Wall St.
How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?
A look at the shareholders of CRISPR Therapeutics AG (NASDAQ:CRSP) can tell us which group is most powerful...
- Yahoo Finance Video
Getting technical: Buyers in control of Crispr Therapeutics (CRSP)
Joining Yahoo Finance's Jen Rogers and Myles Udland is Brian Shannon, CMT and founder of www.alphatrends.net, who breaks down the bullish action in Crispr.
